Novavax shares rise 13% after Moderna advances hantavirus vaccine research.

Novavax stock surged 13.16% following Moderna's announcement of early-stage research on mRNA vaccines targeting hantaviruses, a virus linked to recent cruise ship deaths but unlikely to become a widespread health threat. Moderna is collaborating with the U.S. Army Medical Research Institute and Korea University to develop the vaccine. Meanwhile, Novavax reported quarterly sales of $139.51 million, beating estimates, but posted a net loss of $9 million. The WHO has confirmed several hantavirus cases and deaths, highlighting the importance of vaccine development efforts.